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Division of Vascular Surgery, London Health Sciences Centre & Western University, 800 Commissioners Road East, Room E2-119, London, ON, N6A 5W9, CanadaBe it resolved that we do not need level 1 evidence
comparing best medical treatment (BMT) with thoracic
endovascular aortic repair (TEVAR) in patients with un-
complicated type B aortic dissection (BAD). There is
reasonable level 1 evidence available for subacute/chronic
type B dissection (Investigation of STEnt Grafts in Aortic
Dissection [INSTEAD] trial1) and we concede that the long-
term results of this trial are needed to help clarify initial
ﬁndings. We will argue instead that level 1 evidence for
acute uncomplicated BAD and, consequently, the Acute
Dissection Stent-graft Or Best medical treatment (ADSORB)
trial,2 was not required, nor has it resulted in clinically
applicable information. Rather than focusing on whether all
BADs should be treated with TEVAR or not, we need to
determine which group of patients will ﬁnd the most
beneﬁt. We are well on our way to understanding this
without the need of a randomized trial.
One core issue in the study of BADs is that many of its
features are not uniformly deﬁned. The only generally agreed
upon deﬁnition is that Stanford type B or Debakey III aortic
dissection originates in the descending thoracic aorta without
retrograde extension into the ascending aorta. BADs are
considered complicated if they involve malperfusion or
rupture, but studies are inconsistent on whether they include
other symptoms, such as refractory hypertension and
persistent pain.3 Imaging ﬁndings such as an increase in per-
iaortic hematoma and hemorrhagic pleural effusion clearly
increase morbidity and mortality, but are inconsistently re-
ported.4 Historically, BAD is considered acute when it occurs
within 14 days of symptom onset, while a dissection discov-
ered after 2 weeks is considered chronic. In recent years, the
term “subacute” has been used, further confounding the
temporal classiﬁcation. The INSTEAD trial is the only ran-
domized controlled trial (RCT) of subacute or chronic type B
dissections treated with TEVAR plus BMT versus BMT plus
surveillance.1 Conversely, the ADSORB trial, the 1-year results
of which have recently been published, is the only RCT of
acute type B dissections treated with TEVAR plus BMT versus
BMT.2 BMT generally involves lowering patients’ blood pres-
sure to approximately 120 mmHg systolic over 80 mmHg* Corresponding author. Tel.: þ1 519 667 6794; fax: þ1 519 667 6549.
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supplemented by diuretics, angiotensin-converting enzyme
inhibitors, calcium channel blockers, and sometimes a-
blockers in refractory cases.5e7 TEVAR involves endograft
coverage of the dissection entry tear.
There is overwhelming evidence, albeit mostly from non-
level 1 data, that patients with uncomplicated acute BADs
do well with BMT.6,8 In the International Registry of Acute
Aortic Dissection (IRAD) study, this has resulted in a 10% 30-
day mortality.9 The INSTEAD trial, which looked at sub-
acute/chronic BADs, garnered even better results with BMT
having a 2-year cumulative survival rate of 95.6  2.5%.1 In
order for clinical equipoise to occur, and thus make an
uncomplicated acute BAD RCT clinically relevant, one must
be convinced that there is no superior treatment or, in
other words, that TEVAR is equivalent or better than BMT.
We need to look no further than the ADSORB trial to show
that clinical equipoise has not occurred, which is displayed
in their slow enrollment and low recruitment. As other
critics have pointed out, the slow recruitment with ADSORB
necessitated a power recalculation to permit study
completion, but resulted in the study being underpowered
to demonstrate differences in aortic-related or all-cause
mortality.10 Even though the mortality in acute uncompli-
cated BAD is highest in the ﬁrst 10e14 days, if we can
achieve a 90% 30-day survival rate without intervention,
just how many patients do we expect to beneﬁt in the
short-term from TEVAR? Moreover, the patients at risk for
developing complications with BMT are unlikely to be
completely protected with TEVAR and are, no doubt, the
same patients that would have technically difﬁcult TEVAR
procedures leading to higher morbidity and mortality.
Level 1 evidence is not really achievable owing to the
inability to obtain conventional and clinically relevant end-
points. One of the main criticisms of the INSTEAD trial is
that it was underpowered to detect mortality at 2 years,
which was its primary outcome and, arguably, one of the
few outcomes that might change clinical practice.11 Simi-
larly, the ADSORB trial, was not powered to identify a
mortality difference. In order to do so, it would have
required much larger numbers of patients recruited over
many years, which was simply not feasible. The ADSORB
trial’s composite primary endpoint of false lumen throm-
bosis, aortic dilation at 1 year, and aortic rupture through to
1-year follow-up is unlikely to alter our understanding of the
treatment of BAD. Looking at the results, there has been
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lumen diameter and decrease in false lumen diameter at 1
year (p < .001), despite there being no overall change in
maximal diameter of the descending thoracic aorta.2
Indeed, inducing false lumen thrombosis and aortic
remodeling has been shown in some studies to have
improved patient outcomes over time,12,13 but they are
scarcely the hard endpoints that we need in a randomized
trial to change clinical practice. Treating all acute BADs with
TEVAR to promote favorable aortic remodeling is akin to
repairing all small abdominal aortic aneurysms to prevent
aneurysm dilation.
In the end, even when the long-term results of ADSORB
are completed and published, they will not solve the
questions that we need answered. Rather than a random-
ized trial that attempts to tell us whether TEVAR or BMT is
best for all uncomplicated acute type B dissections, we
need a study that tells us which dissections will become
complicated and thus need TEVAR. The INSTEAD trial has
shown that a complication-speciﬁc approach for subacute/
chronic dissections rather than a blanket TEVAR approach is
likely best.11 Risk factors are emerging from IRAD data and
other studies to help better identify the patients that might
beneﬁt from early TEVAR. Gender, ethnicity, underlying
connective tissue disorders, intramural hematoma, false
lumen patency or partial thrombosis, early dilation, smaller
diameters at presentation, and even visceral and renal ar-
tery involvement all inﬂuence the risk of subsequent aortic
dilation.4,14 Furthermore, as diagnostic imaging continues
to improve, and our use and understanding of computa-
tional ﬂuid dynamics increases, we come closer to deﬁning
a BAD population that might truly beneﬁt from interven-
tion.15 Until we more accurately identify these patients and
achieve the clinical equipoise required for an RCT,
attempting to attain level 1 evidence for the treatment of
all uncomplicated BADs is not needed.
As the ADSORB trial has unfortunately shown, it is not
possible to perform a sufﬁciently powered RCT with clini-
cally relevant endpoints comparing TEVAR and BMT in
acute BADs in a timely fashion. It took 10 years for ADSORB
to complete recruitment to deliver an underpowered study
with a power recalculation and a composite endpoint.
Further information is required regarding which acute dis-
sections require TEVAR. However, such an area is where
properly performed registries have clear advantages over
the “level 1” evidence that RCTs provide.REFERENCES
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